

Section III: Comparative Industry Analysis & Classification Framework (Investor and M&A Guide) is devoted to an in-depth comparative and quantitative analysis of the entire AI for Drug Discovery landscape, specifically tuned for investors and business analysts who wish to gain a deeper understanding of the industry in Q2 of 2018.

- **Chapter XI: Classification/Ratings of AI for Advanced R&D and Drug Discovery Companies** performs a quantitative analysis of many of the AI for Drug Discovery companies covered and profiled in this report using a variety of tangible metrics that can be used to acquire an understanding of their level of scientific validation and industry activity, including the proportion of AI specialists among their total staff, number of publications, number of patents, etc. It then uses these metrics to rank AI for Drug Discovery companies side by side, and to build a classification framework by which these companies can be better categorized according to their specific focus, application and industry segmentation.
- **Chapter XII: 2010 - 2016 - Investment Rounds, M&A Deals and Notable Events** summarizes some of the most notable investment rounds, M&As and other notable events from 2010-2016, including but not limited to Benevolent AI's \$87M raise, ThoughtSpot's \$100M raise and Meta's \$23M raise.
- **Chapter XIII: 2017 - Investment Rounds, M&A Deals and Notable Events** summarizes some of the most notable investment rounds, M&As and other notable events in 2017, including but not limited to Exscientia's €250M raise, AICure's \$15M raise and Insilico Medicine's \$10M raise.
- **Chapter XIV: Q1 2018 - Investment Rounds, M&A Deals and Notable Events** summarizes some of the most notable investment rounds, M&As and other notable events in Q1 of 2018, including but not limited to AtomWise's \$45M raise, XtalPi's \$15M raise, and twoXAR's \$10M raise.
- **Chapter XV: Q2 2018 - Investment Rounds, M&A Deals and Notable Events** summarizes the major investments, M&As and other notable events (e.g. joint ventures, public announcements, etc.) that have occurred within the AI for Drug Discovery space specifically in Q2 of 2018, including but not limited to ThoughtSpot's \$145M raise, Benevolent.AI's \$115M raise, Celsius Therapeutics' \$65M raise, and Datavant's \$40.5M raise